



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/559,835	12/06/2005	Takehisa Matsuda	2005_1807A	7978
513 7590 10/03/2007 WENDEROTH, LIND & PONACK, L.L.P. 2033 K STREET N. W. SUITE 800 WASHINGTON, DC 20006-1021			EXAMINER LEAVITT, MARIA GOMEZ	
			ART UNIT 1633	PAPER NUMBER
			MAIL DATE 10/03/2007	DELIVERY MODE PAPER

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

# Office Action Summary

Application No.

10/559,835

Applicant(s)

MATSUDA ET AL.

Examiner

Maria Leavitt

Art Unit

1633

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

## Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

## Status

- 1) ☒ Responsive to communication(s) filed on 06 December 2005.
- 2a) ☐ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

## Disposition of Claims

- 4) ☒ Claim(s) 1-17 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☐ Claim(s) \_\_\_\_\_ is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☒ Claim(s) 1-17 are subject to restriction and/or election requirement.

## Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

## Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
  - ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

## Attachment(s)

- ☐ Notice of References Cited (PTO-892)
- ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- ☐ Information Disclosure Statement(s) (PTO/SB/08)  
Paper No(s)/Mail Date \_\_\_\_\_
- ☐ Interview Summary (PTO-413)  
Paper No(s)/Mail Date. \_\_\_\_\_
- ☐ Notice of Informal Patent Application
- ☐ Other: \_\_\_\_\_

*DETAILED ACTION*

Election/Restrictions

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

- I. Claims 1-6 and 8-13 drawn to a cell containing preparations comprising a DNA sequence and a fibrous protein.
- II. Claim 14, drawn to a method for inhibiting growth of cancers comprising administering a cell-containing preparation comprising a DNA sequence and a fibrous protein.
- III. Claims 15 and 16 drawn to a method for producing a cell-containing preparation comprising culturing a cell on the surface of a fibrous protein and transforming the cultured cells with a recombinant expression vector.
- IV. Claims 17, drawn to a method for producing a cell-containing preparation comprising transforming the cultured cell with a recombinant expression vector and mixing the resulting transformant with a fibrous protein.

The inventions listed as Groups I-IV do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical reasons:

37 CFR 1.475 (c) states:

“If an application contains to more or less than one of the combinations of categories of invention set forth in paragraph (b) of this section, unity of invention might not be present”

37 CFR 1.475 (d) also states:

“If multiple products, processes of manufacture, or uses are claimed, the first invention of the category first mentioned in the claims of the application and the first recited invention of each of the other categories related thereto will be considered as the main invention in the claims, see PCT article 17(3)(a) and 1.476(c)”.

The inventions listed as Groups I-IV do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical reasons: the technical feature linking Groups I-IV appears to be that they all relate to a cell-containing preparation and methods for providing NK4 (hepatocyte growth factor antagonist) to suppress invasion, metastasis and angiogenesis of cancer tissue. However, prior art has described a cell-based protein delivery system for the inhibition of the growth of pancreatic cancer comprising local administration of a NK4 secreted form an NK4-transduced epithelial cell sheet (Manabe et al., Clinical Cancer Research, 2003, 3518-3166). Therefore, the technical feature linking the invention of groups I-IV does not constitute a special technical feature as defined by PCT Rule 13.2, as it does not define a contribution over prior art for the reasons set forth above.

The inventions listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical reasons:

A method for producing a cell-containing preparation as claimed in Group III is functionally different from the method claimed in Group IV, the method of Group III merely requires growing the cell culture on the surface of a fibrous protein and transforming said cells

whereas the method of Group IV requires mixing the transformant cells with a fibrous protein which is not required by the method of Group III. Further, the invention of Group II is drawn to a method for inhibiting the growth of cancer cells comprising administration of a cell-containing preparation which steps are distinct from the ones claimed in Group III or IV. Hence inventions of Groups II-IV are drawn to methodologies with different modes of operation, each being used in different capacities, having different functions and producing different effects. Moreover, the invention of Group I is drawn to a cell-containing preparation that may be transformed with a vector (e.g., retrovirus, herpes virus, and others. The inventions of Groups I-IV are not coextensive. Because these inventions are distinct for the reasons given above, and are separately classified and searched, it would be unduly burdensome for the examiner to search and examine all of the subject matter being sought in the presently pending claims, and thus, restriction for examination purposes as indicated is proper.

In addition, if any of inventions I-VI are elected, a **further restriction** is required between compositions and methods which involve a base sequence represented by SEQ ID No: 1 or SEQ ID No: 2, which are each distinct nucleic acid coding sequences which encode specific and unique polypeptides. As such, each nucleic acid does not overlap in scope with the others, are not obvious variants, and have materially different functions. Therefore, the search for each nucleic acid sequence is not co-extensive and it would place an undue burden on the examiner to search and examine all of these inventions together. **Applicants must elect one specific nucleotide SEQ ID NO encoding a corresponding polypeptide sequence.**

Species restriction

Should group II be elected, a species restriction is further required under 35 U.S.C. 121 and 372, wherein a species election(s) must correspond to an elected group as indicated above.

1) A recombinant expression vector as recited in **claim 7**, selected from one of the following vectors:

- i) adeno-associated virus (AAV),
- ii) retrovirus,
- iii) poxvirus,
- iv) herpes virus
- v) herpes simplex virus
- vi) lentivirus (HIV)
- vii) Sendai virus
- viii) Epstein-Barr virus (EBV)
- ix) vaccinia virus
- x) SV40, and
- xi) Plasmid

The species are independent or distinct because there are cell-containing preparations comprising **vectors** having different chemical structures, physical properties, and biological functions as a result of containing different chemical compounds or expressed genes. For example, use of retroviruses have risks, as insertion of retroviral genes into the host genome may occur at random locations, in contrast adenoviruses are used for localized *in vivo* treatment

Art Unit: 1633

because avoid the risk associated with permanently altering the host cell genotype or promoting insertional mutagenesis. Thus, the combined features of a particular species, distinct structurally and functionally, would not necessarily overlap with one another when a prior art search is conducted.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, at least claim 1 is generic.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Art Unit: 1633

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Maria Leavitt whose telephone number is 571-272-1085. The examiner can normally be reached on M-F.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph Woitach, Ph.D can be reached on (571) 272-0739. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

To aid in correlating any papers for this application, all further correspondence regarding this application should be directed to Group Art Unit 1633; Central Fax No. (571) 273-8300. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also

Art Unit: 1633

enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public.

Maria Leavitt, PhD  
Patent Examiner P/1633  
Remsen 2B55  
Phone: 571-272-1085

*/Anne Marie S. Wehbe/*  
Primary Examiner, A.U. 1633